At a glance
ClinicalIndex Comparison RecordN/ACompleted· 47 enrolled
Drug / intervention
Anagrelide hydrochloridedrug
Likely dose
0.5 mg hard capsules, dose adjusted by treating physicianAI-extracted
Key inclusion· 4
- ✓Confirmed diagnosis of Essential Thrombocythemia according to WHO criteria
- ✓ET uncontrolled by first-line or previous cytoreductive treatment due to inadequate efficacy or intolerance
- ✓Recently commenced anagrelide hydrochloride (within 7 days) or documented decision to commence
- ✓Able to understand and willing to provide informed consent
Key exclusion· 4
- ✕Contraindication to anagrelide hydrochloride per XAGRID SmPC
- ✕Known or suspected intolerance or hypersensitivity to anagrelide or related compounds
- ✕Participation in an interventional research study
- ✕Concurrent or planned cytoreductive agent therapy (excluding aspirin and anti-aggregatory products)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)
In Brief
An observational study evaluating Anagrelide hydrochloride for Essential Thrombocythemia (ET). Completed, enrolled 47 participants across 10 sites.
Detailed Summary
This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Thrombocythemia (ET)
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJul 2011
Primary CompletionSep 2013
TodayJul 2026
First PostedMay 12, 2011
Enrollment StartJul 19, 2011
Primary CompletionSep 19, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.1 years ago
Interventions
Anagrelide hydrochloridedrug
0.5 mg hard capsules, dosing decisions will be made by the treating physician